According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other analysts have also issued reports on MCRB. FBR & Co reiterated a buy rating on shares of Seres Therapeutics in a report on Friday, July 8th. Leerink Swann reiterated a buy rating and issued a $43.00 price target on shares of Seres Therapeutics in a report on Thursday, July 14th. Cowen and Company reiterated a buy rating on shares of Seres Therapeutics in a report on Tuesday, July 19th. HC Wainwright started coverage on Seres Therapeutics in a report on Friday, July 29th. They issued a buy rating and a $50.00 price target for the company. Finally, Bank of America Corp. lowered Seres Therapeutics from a buy rating to a neutral rating in a report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $31.57.
Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 11.35 on Wednesday. The firm has a 50 day moving average price of $11.85 and a 200-day moving average price of $22.50. Seres Therapeutics has a 12-month low of $8.05 and a 12-month high of $44.51. The company’s market cap is $457.11 million.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.24. The business earned $3 million during the quarter, compared to analyst estimates of $4.20 million. During the same period in the previous year, the business earned ($1.45) EPS. Seres Therapeutics’s revenue for the quarter was up NaN% on a year-over-year basis. On average, equities analysts expect that Seres Therapeutics will post ($2.33) earnings per share for the current fiscal year.
In other news, insider Michele Trucksis sold 4,156 shares of the company’s stock in a transaction on Thursday, July 28th. The stock was sold at an average price of $35.18, for a total transaction of $146,208.08. Following the transaction, the insider now directly owns 4,156 shares of the company’s stock, valued at $146,208.08. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John G. Aunins sold 9,390 shares of the company’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $10.87, for a total value of $102,069.30. Following the transaction, the insider now directly owns 192,125 shares in the company, valued at $2,088,398.75. The disclosure for this sale can be found here. Company insiders own 41.90% of the company’s stock.
Several institutional investors have recently modified their holdings of MCRB. Birchview Capital LP acquired a new position in shares of Seres Therapeutics during the second quarter worth about $145,000. Pacad Investment Ltd. acquired a new position in shares of Seres Therapeutics during the second quarter worth about $198,000. First Mercantile Trust Co. acquired a new position in shares of Seres Therapeutics during the second quarter worth about $229,000. GSA Capital Partners LLP acquired a new position in shares of Seres Therapeutics during the second quarter worth about $273,000. Finally, American International Group Inc. increased its position in shares of Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock worth $298,000 after buying an additional 5,290 shares during the last quarter. 78.27% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.